RxDoctor Payments Data

Jay Markham, MD

Cardiovascular Disease · Springfield, MANPI 1427022508

Payments from drug & device makers

$2,228in general payments, 2019–2025

Across 106 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$443
  • Pfizer$360
  • E.r. Squibb & Sons, L.L.C.$259
  • Boehringer Ingelheim$211
  • Johnson & Johnson$159
  • Amgen$155
  • plus $640 from 12 others

What the payments were for

  • Food & beverage$2,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,228 in reported general payments places this provider in the 50th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$157,703
Medicare patients
984
Services billed
1,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban529$587,571
EntrestoSacubitril/Valsartan183$240,840
XareltoRivaroxaban169$202,592
FarxigaDapagliflozin Propanediol54$64,286
JardianceEmpagliflozin68$57,450
Repatha SureclickEvolocumab65$48,018
MultaqDronedarone Hcl15$28,427
Praluent PenAlirocumab26$20,694
Repatha SyringeEvolocumab19$14,089
Metoprolol Succinate687$12,744
BrilintaTicagrelor14$12,330
Atorvastatin Calcium518$9,311
Diltiazem 24hr Er (Cd)Diltiazem Hcl158$5,246
Rosuvastatin Calcium135$4,353
Enoxaparin Sodium18$3,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$360$587,571529 claims
NovartisEntresto$443$240,840183 claims
Johnson & JohnsonXarelto$159$202,592169 claims
AstraZenecaFarxiga, Brilinta$55$76,61768 claims
Boehringer IngelheimJardiance$211$57,45068 claims
Sanofi-aventis U.S. LLCMultaq$40$28,42715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →